Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Core Insights - Humacyte, Inc. has received a U.S. Patent for a bioengineered esophagus, which is designed for patients with esophageal damage, providing protection until 2041 [1][2] - The patent covers key structural and mechanical attributes necessary for the esophageal replacement, including size and strength [1] - Humacyte's patent portfolio now includes coverage for bioengineered trachea, esophagus, and urinary conduits across multiple regions including the U.S., Europe, Canada, and Australia [2] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable bioengineered human tissues and advanced tissue constructs [5] - The company is advancing a portfolio of acellular tissue engineered vessels (ATEVs) currently in late-stage clinical trials for various vascular applications [5] - Humacyte's ATEV for vascular trauma received FDA approval in December 2024, and it has also received RMAT and Fast Track designations [5] Product Pipeline - The company is working on advanced tissue constructs for tracheal, esophageal, and urinary conduit replacements, with plans for further optimization and testing in large animal models [3] - Other products in the pipeline include Coronary Tissue Engineered Vessels (CTEV) and the BioVascular Pancreas™ (BVP™), all utilizing the same bioengineering technology [3] Strategic Direction - Humacyte aims to expand its bioengineered tissue platform and is looking to partner with corporate entities to accelerate the development of its product candidates [4]